Association of complement receptor 1 gene polymorphisms with cognitive function

Previous evidence suggest involvement of the complement receptor 1 (CR1) in development of Alzheimer’s disease. We investigated the association of CR1 gene polymorphisms with cognitive function in older subjects. Single nucleotide polymorphisms (SNPs) within the CR1 region on chromosome 1 (n = 73) were assessed in 5,244 participants in the PROspective Study of Pravastatin in the Elderly at Risk (51.9% female, mean age 75.3 yr). Linear regression, adjusted for age, sex, country, and use of pravastatin, was used to assess the association between the SNPs and cognitive function. All 73 SNPs within the genomic region of the CR1 gene on chromosome 1 were extracted. Eighteen were independent, according to a relatively stringent R2 threshold of >0.8 with LDlink. Twelve of the 18 investigated CR1 SNPs were significantly associated with a decline in cognitive function (all P < 0.05). These data indicate that genetic variation within the CR1 gene is associated not only with Alzheimer’s disease, but also with general cognitive function during late life.

[1]  R. Mahmoudi,et al.  High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment , 2017, Journal of visualized experiments : JoVE.

[2]  J. Jukema,et al.  Complement receptor 1 gene polymorphisms are associated with cardiovascular risk , 2016, Atherosclerosis.

[3]  J. Rogers,et al.  Analysis of the Putative Role of CR1 in Alzheimer’s Disease: Genetic Association, Expression and Function , 2016, PloS one.

[4]  Mitchell J. Machiela,et al.  LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants , 2015, Bioinform..

[5]  John D. Lambris,et al.  Complement in Immune and Inflammatory Disorders: Pathophysiological Mechanisms , 2013, The Journal of Immunology.

[6]  N. Sattar,et al.  PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population[S] , 2013, Journal of Lipid Research.

[7]  N. Sattar,et al.  Genome-Wide Study of Gene Variants Associated with Differential Cardiovascular Event Reduction by Pravastatin Therapy , 2012, PloS one.

[8]  N. Sattar,et al.  Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses , 2011, BMC Medical Genetics.

[9]  Jason J. Corneveaux,et al.  CR1 is associated with amyloid plaque burden and age‐related cognitive decline , 2011, Annals of neurology.

[10]  K. Lunetta,et al.  Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. , 2010, Archives of neurology.

[11]  Kewei Chen,et al.  Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. , 2010, Human molecular genetics.

[12]  V. Pankratz,et al.  Replication of CLU, CR1, and PICALM associations with alzheimer disease. , 2010, Archives of neurology.

[13]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[14]  A. Blom,et al.  Complement activation and inhibition: a delicate balance. , 2009, Trends in immunology.

[15]  Beth Stevens,et al.  The complement cascade: Yin–Yang in neuroinflammation – neuro‐protection and ‐degeneration , 2008, Journal of neurochemistry.

[16]  P. Macfarlane,et al.  Testing cognitive function in elderly populations: the PROSPER study , 2002, Journal of neurology, neurosurgery, and psychiatry.

[17]  P. Macfarlane,et al.  The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.

[18]  J. Jolles,et al.  Learning and retrieval rate of words presented auditorily and visually. , 1985, The Journal of general psychology.

[19]  D. Fearon.  Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte , 1980, The Journal of experimental medicine.

[20]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[21]  P. Macfarlane,et al.  Pravastatin and cognitive function in the elderly. Results of the PROSPER study , 2009, Journal of Neurology.

[22]  H. Kulbertus,et al.  [The PROSPER Study (PROspective study of pravastatin in the elderly at risk)]. , 2002, Revue medicale de Liege.

[23]  J. Jolles,et al.  Effect of test duration on age-related differences in Stroop interference. , 1997, Journal of clinical and experimental neuropsychology.

[24]  J. Jolles,et al.  Stroop interference: aging effects assessed with the Stroop Color-Word Test. , 1993, Experimental aging research.

[25]  A. Rey.  L'examen psychologique dans les cas d'encéphalopathie traumatique. (Les problems.). , 1941 .